中华麻醉学杂志
中華痳醉學雜誌
중화마취학잡지
CHINESE JOURNAL OF ANESTHESIOLOGY
2015年
2期
154-157
,共4页
张颖%赵其宏%顾尔伟%李晓红%王南海
張穎%趙其宏%顧爾偉%李曉紅%王南海
장영%조기굉%고이위%리효홍%왕남해
右美托咪啶%心肺转流术%肠黏膜%心脏瓣膜假体植入
右美託咪啶%心肺轉流術%腸黏膜%心髒瓣膜假體植入
우미탁미정%심폐전류술%장점막%심장판막가체식입
Dexmedetomidine%Cardiopulmonary bypass%Intestinal mucosa%Heart valve prosthesis implantation
目的 评价右美托咪定对体外循环(CPB)下心脏瓣膜置换术患者肠黏膜损伤的影响.方法 择期行心脏瓣膜置换术的风湿性心脏病患者40例,性别不限,年龄32 ~ 64岁,体重40~75 kg,ASA分级Ⅱ或Ⅲ级,NYHA心功能分级Ⅱ或Ⅲ级,采用随机数字表法,将患者分为2组(n=20):对照组(C组)和右美托咪定组(D组).全麻诱导气管插管后行机械通气,麻醉维持:吸入0.8%~2.0%七氟醚,间断静脉注射舒芬太尼0.5~ 1.0 μg/kg和维库溴铵0.04~ 0.06 mg/kg.D组于常规麻醉诱导前经10 min静脉注射右美托咪定1μg/kg负荷量,随后以0.3 μg·kg-1· h-1速率静脉输注至术毕.分别于CPB开始前、主动脉阻断后30 min、CPB结束时、术毕、术后6h、术后24 h时采集中心静脉血样,采用ELISA法检测血浆TNF-α、IL-6、IL-10和肠型脂肪酸结合蛋白的浓度,采用比浊光度法测定血浆内毒素浓度.记录术后机械通气时间与ICU停留时间.结果 与C组比较,D组血浆TNF-α、IL-6、IL-10、肠型脂肪酸结合蛋白和内毒素的浓度降低,术后机械通气时间和ICU停留时间缩短(P<0.05).结论 常规麻醉诱导前静脉输注右美托咪定1 μg/kg负荷量,随后以0.3 μg· kg-1 ·h-1速率输注至术毕可减轻CPB下心脏瓣膜置换术患者肠黏膜损伤.
目的 評價右美託咪定對體外循環(CPB)下心髒瓣膜置換術患者腸黏膜損傷的影響.方法 擇期行心髒瓣膜置換術的風濕性心髒病患者40例,性彆不限,年齡32 ~ 64歲,體重40~75 kg,ASA分級Ⅱ或Ⅲ級,NYHA心功能分級Ⅱ或Ⅲ級,採用隨機數字錶法,將患者分為2組(n=20):對照組(C組)和右美託咪定組(D組).全痳誘導氣管插管後行機械通氣,痳醉維持:吸入0.8%~2.0%七氟醚,間斷靜脈註射舒芬太尼0.5~ 1.0 μg/kg和維庫溴銨0.04~ 0.06 mg/kg.D組于常規痳醉誘導前經10 min靜脈註射右美託咪定1μg/kg負荷量,隨後以0.3 μg·kg-1· h-1速率靜脈輸註至術畢.分彆于CPB開始前、主動脈阻斷後30 min、CPB結束時、術畢、術後6h、術後24 h時採集中心靜脈血樣,採用ELISA法檢測血漿TNF-α、IL-6、IL-10和腸型脂肪痠結閤蛋白的濃度,採用比濁光度法測定血漿內毒素濃度.記錄術後機械通氣時間與ICU停留時間.結果 與C組比較,D組血漿TNF-α、IL-6、IL-10、腸型脂肪痠結閤蛋白和內毒素的濃度降低,術後機械通氣時間和ICU停留時間縮短(P<0.05).結論 常規痳醉誘導前靜脈輸註右美託咪定1 μg/kg負荷量,隨後以0.3 μg· kg-1 ·h-1速率輸註至術畢可減輕CPB下心髒瓣膜置換術患者腸黏膜損傷.
목적 평개우미탁미정대체외순배(CPB)하심장판막치환술환자장점막손상적영향.방법 택기행심장판막치환술적풍습성심장병환자40례,성별불한,년령32 ~ 64세,체중40~75 kg,ASA분급Ⅱ혹Ⅲ급,NYHA심공능분급Ⅱ혹Ⅲ급,채용수궤수자표법,장환자분위2조(n=20):대조조(C조)화우미탁미정조(D조).전마유도기관삽관후행궤계통기,마취유지:흡입0.8%~2.0%칠불미,간단정맥주사서분태니0.5~ 1.0 μg/kg화유고추안0.04~ 0.06 mg/kg.D조우상규마취유도전경10 min정맥주사우미탁미정1μg/kg부하량,수후이0.3 μg·kg-1· h-1속솔정맥수주지술필.분별우CPB개시전、주동맥조단후30 min、CPB결속시、술필、술후6h、술후24 h시채집중심정맥혈양,채용ELISA법검측혈장TNF-α、IL-6、IL-10화장형지방산결합단백적농도,채용비탁광도법측정혈장내독소농도.기록술후궤계통기시간여ICU정류시간.결과 여C조비교,D조혈장TNF-α、IL-6、IL-10、장형지방산결합단백화내독소적농도강저,술후궤계통기시간화ICU정류시간축단(P<0.05).결론 상규마취유도전정맥수주우미탁미정1 μg/kg부하량,수후이0.3 μg· kg-1 ·h-1속솔수주지술필가감경CPB하심장판막치환술환자장점막손상.
Objective To evaluate the effect of dexmedetomidine on the intestinal mucosal injury in the patients undergoing cardiac valve replacement with cardiopulmonary bypass (CPB).Methods Forty patients of both sexes with rheumatic heart disease,aged 32-64 yr,weighing 40-75 kg,of ASA physical status Ⅱ or Ⅲ (NYHA class Ⅱ or Ⅲ),scheduled for elective cardiac valve replacement with CPB,were randomly divided into 2 groups (n =20 each) using a random number table:control group (group C) and dexmedetomidine group (group D).After induction of anesthesia,the patients were endotracheally intubated and mechanically ventilated.Anesthesia was maintained with 0.8%-2.0% sevoflurane inhalation and intermittent iv boluses of sufentanil 0.5-1.0 μg/kg and vecuronium 0.04-0.06 mg/kg.Before routine induction of anesthesia,a loading dose of dexmedetomidine 1 μg/kg was injected intravenously over 10 min,followed by continuous infusion at 0.3 μg · kg-1 · h-1 until the end of surgery in group D,while the equal volume of normal saline was given in group C.Before CPB,at 30 min after aortic clamping,at the termination of CPB,at the end of surgery and at 6 and 24 h after surgery,central venous blood samples were taken for determination of concentrations of tumor necrosis factor-alpha,interleukin-6 (IL-6) and IL-10 and intestinal fatty acid binding protein in plasma (by ELISA),and the plasma concentration of endotoxin (using turbidimetry).The time of postoperative mechanical ventilation and duration of ICU stay were recorded.Results Compared with group C,the concentrations of tumor necrosis factor-alpha,IL-6,IL-10 and endotoxin and intestinal fatty acid binding protein in plasma were significantly decreased,and the time of postoperative mechanical ventilation and duration of ICU stay were shortened in group D.Conclusion Dexmedetomidine infused continuously at 0.3 μg · kg-1 · h-1 (until the end of surgery) after a loading dose of 1 μg/kg before routine induction of anesthesia can reduce intestinal mucosal injury in the patients undergoing cardiac valve replacement with CPB.